| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:828-835.)
© 2005 American Heart Association, Inc.
Exercise Physiology |
From the Adult Congenital Heart Program, Department of Cardiology, Royal Brompton Hospital (G.-P.D., K.D., W.L., S.V.B.-N., C.S.B., B.J., B.B., M.J.M., M.A.G.); Department of Clinical Cardiology, National Heart and Lung Institute, Imperial College (G.-P.D., D.O., P.A.P.-W.); and Cardiac Performance Unit, Department of Cardiology, St Marys Hospital (D.P.F.), London, UK.
Correspondence to Professor Michael A. Gatzoulis, MD, PhD, FACC, Adult Congenital Heart Program, Royal Brompton Hospital, Sydney St, SW3 6NP London, UK. E-mail m.gatzoulis{at}rbh.nthames.nhs.uk
Received December 15, 2004; revision received April 20, 2005; accepted April 28, 2005.
| Abstract |
|---|
|
|
|---|
Methods and Results Cardiopulmonary exercise testing was performed in 335 consecutive ACHD patients (age, 33±13 years), 40 noncongenital heart failure patients (age, 58±15 years), and 11 young (age, 29±5 years) and 12 older (age, 59±9 years) healthy subjects. Peak oxygen consumption (peak
O2) was reduced in ACHD patients compared with healthy subjects of similar age (21.7±8.5 versus 45.1±8.6; P<0.001). No significant difference in peak
O2 was found between ACHD and heart failure patients of corresponding NYHA class (P=NS for each NYHA class). Within ACHD subgroups, peak
O2 gradually declined from aortic coarctation (28.7±10.4) to Eisenmenger (11.5±3.6) patients (P<0.001). Multivariable correlates of peak
O2 were peak heart rate (r=0.33), forced expiratory volume (r=0.33), pulmonary hypertension (r=0.26), gender (r=0.23), and body mass index (r=0.19). After a median follow-up of 10 months, 62 patients (18.5%) were hospitalized or had died. On multivariable Cox analysis, peak
O2 predicted hospitalization or death (hazard ratio, 0.937; P=0.01) and was related to the frequency and duration of hospitalization (P=0.01 for each).
Conclusions Exercise capacity is depressed in ACHD patients (even in allegedly asymptomatic patients) on a par with chronic heart failure subjects. Lack of heart rate response to exercise, pulmonary arterial hypertension, and impaired pulmonary function are important correlates of exercise capacity, as is underlying cardiac anatomy. Poor exercise capacity identifies ACHD patients at risk for hospitalization or death.
Key Words: exercise test heart defects, congenital heart failure prognosis survival
| Introduction |
|---|
|
|
|---|
Quantifying exercise capacity by measurement of peak oxygen consumption (peak
O2) is an established investigation in the management of patients with chronic heart failure,3,4 but corresponding studies in ACHD either have been restricted to isolated patient groups or have reported on data acquired over >1 decade.510 As a result, it is unclear whether different cardiac lesions cause different degrees of exercise intolerance and whether there is any prognostic value in formal measurement of peak
O2 in the ACHD population. Identifying the factors associated with impaired peak
O2 may help to improve our understanding of the physiological derangement and ultimately may assist in targeting clinical care for ACHD patients.
The aims of our study were (1) to evaluate objective exercise capacity in a large cohort of ACHD patients, (2) to clarify correlates of exercise capacity across the anatomic spectrum of ACHD, and (3) to investigate whether the degree of objective exercise intolerance has prognostic implications in these patients.
| Methods |
|---|
|
|
|---|
90% in air after 2 minutes of complete rest. The presence of pulmonary arterial hypertension was also recorded on the basis of Doppler echocardiography (estimated systolic right ventricular pressure >35 mm Hg in the absence of pulmonary stenosis) and/or cardiac catheterization data according to current guidelines.11
Measurements
Cardiopulmonary exercise testing was performed on a treadmill according to a modified Bruce protocol12,13 with the addition of a "stage 0" in which the patient walks at a velocity of 1 mile/h and a gradient of 5% for 3 minutes. All subjects were encouraged to exercise to exhaustion regardless of the maximal heart rate achieved. Ventilation, oxygen uptake, and carbon dioxide production were measured continuously with a respiratory mass spectrometer (Amis 2000, Innovision). The peak respiratory exchange ratio (RER) was calculated as the ratio of carbon dioxide production to oxygen consumption at peak exercise. Heart rate was measured by continuous electrocardiography, and arterial blood pressure was recorded manually by sphygmomanometry.
Standard spirometry was available in 160 patients. Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were measured before exercise testing and are expressed as percentages of predicted values.
Systemic and subpulmonary ventricular function (systemic) was assessed semiquantitatively by an experienced echocardiographer (n=273) blinded to the exercise data and quantified as previously described.14 The following grades were used: 1=normal, 2=mildly impaired, 3=moderately impaired, and 4=severely impaired systolic function.
Patients were followed up after exercise testing, and the time taken to reach an end point of death or hospitalization at our institution was recorded.
Healthy volunteer data were obtained from cardiopulmonary exercise tests undergone by healthy subjects for research projects at our institution using the same exercise protocol and measurement equipment as ACHD patients.
Statistical Analysis
All values are presented as mean±SD. Comparisons between groups were made with Student t test, Mann-Whitney U test, or the
2 test as appropriate. For statistical analysis, NYHA class was considered a continuous variable, and Spearman rank correlation was used to estimate correlation between NYHA class and peak
O2. Relationships between variables were initially studied by single-variable regression, with significant variables subsequently incorporated into stepwise forward multiple regression models. Single-variable Cox proportional-hazards analysis was used to assess the association between variables and hospitalization-free survival. Significant single-variable prognosticators were subsequently included in a multivariable Cox proportional-hazards analysis (stepwise forward). For all analyses, a value of P<0.05 was considered significant. Receiver-operating characteristic curve analysis was used to assess area under the curve. The relationship between variables and the frequency or duration of hospitalization was assessed with a zero-inflated negative binomial regression model, which accounts for the number or length of hospitalization and the time at risk and deals with the excess number of patients with 0 hospitalizations. SPSS (SPSS Inc) was used for all the analyses except for the zero-inflated negative binomial regression, which was analyzed with Stata 7.0 for Windows (Stata Corp).
| Results |
|---|
|
|
|---|
|
|
Impact of Underlying Cardiac Lesion on Exercise Capacity
A gradual decline in peak
O2 was found across the spectrum of congenital heart disease (Figure 1). Patients after repair of aortic coarctation demonstrated the highest peak
O2 values (28.7±10.4 mL · kg1 · min1). Patients with congenitally corrected TGA (18.6±6.9 mL · kg1 · min1), complex anatomy (14.6±4.7 mL · kg1 · min1), and Eisenmenger physiology (11.5±3.6 mL · kg1 · min1) demonstrated the worst exercise capacity (P<0.0001, ANOVA). This result persisted after inclusion of age and gender as possible confounders in an ANCOVA (P<0.001).
|
Depressed Peak
O2, Even in Asymptomatic Patients
Peak
O2 was reduced in ACHD patients compared with healthy subjects of similar age (21.7±8.5 versus 45.1±8.6 mL · kg1 · min1; P<0.0001). Even supposedly asymptomatic ACHD patients (NYHA I) showed dramatically lower peak
O2 values (Figure 2) than healthy subjects of similar age (26.1±8.2 versus 45.1±8.6 mL · kg1 · min1; P<0.0001). In fact, ACHD patients had peak
O2 values equivalent to those of heart failure patients of corresponding NYHA class (Figure 3). This equivalence of peak
O2 values between conditions occurred despite the great disparity in peak
O2 between the corresponding age reference groups (45.1±8.6 versus 28.0±3.5 mL · kg1 · min1; P<0.0001). Exercise capacity declined gradually between functional classes in ACHD (Figure 3).
|
|
Correlates of Peak
O2
On single-variable regression analysis, several characteristics were related to exercise capacity: age, age at surgery, gender, body mass index, %FEV1, %FVC, systemic and pulmonary ventricular function, presence of a residual left-to-right shunt, pulmonary arterial hypertension, cyanosis, and NYHA class (Table 3). During exercise testing, peak heart rate and peak systolic blood pressure were also associated with peak
O2 in single-variable analysis. No significant correlation was found between resting heart rate, resting blood pressure, QRS duration, creatinine or sodium, and peak
O2 values.
|
Including the significant predictors of peak
O2 on single-variable analysis (except age at surgery and residual left-to-right shunts that, by definition, would exclude unoperated patients and single-ventricular physiology) in multivariable analysis revealed that peak heart rate, %FEV1, pulmonary arterial hypertension, gender, and body mass index remained correlated with peak
O2 (R2=0.53; Table 4). Systemic and pulmonary ventricular function was not retained in this model. When systemic and pulmonary ventricular function was subsequently excluded from the multivariable analysis (thus increasing the number of observations used for analysis), the significant correlates of peak
O2 were peak heart rate, gender, body mass index, %FEV1, pulmonary hypertension, NYHA class, and cyanosis (R2=0.54).
|
Impact of Cardiac Rhythm, ß-Blockade, and Pacemakers on Peak
O2
Patients in sinus rhythm at the time of exercise testing had a higher peak heart rate (156.1±29.8 versus 140.4±39.5 bpm; P=0.003) and a higher peak
O2 (22.1±8.6 versus 18.5±7.1 mL · kg1 · min1; P=0.015). There were too few patients in atrial fibrillation or atrial flutter for subanalysis for a potential effect of different types of arrhythmia on peak
O2. Patients on ß-blockade (n=36) had lower peak heart rate (130.8±39.8 versus 157.3±29.3 bpm; P<0.0001) and peak
O2 (17.9±8.0 versus 22.1±8.3 mL · kg1 · min1; P<0.0001). Similarly, patients with a permanent pacemaker also had lower values of peak heart rate (133.6±25.9 versus 156.0±31.3 bpm; P<0.001). However, there was only a trend toward lower peak
O2 in this latter group (19.5±7.1 versus 21.9±8.6 mL · kg1 · min1; P=0.17).
Pulmonary Function, Reasons for Test Termination, and Impact of Respiratory Exchange Ratio
Pulmonary function was depressed in ACHD patients (Table 1) but no different between cardiac lesions. The vast majority of patients terminated exercise because of either shortness of breath (n=136) or fatigue (n=142). In 57 patients, other reasons such as presyncope, syncope, arrhythmias, or a substantial drop in oxygen saturations caused test termination. There was no statistically significant difference between reason for test termination and specific diagnostic groups.
Overall, the mean RER in ACHD patients was 1.04±0.13. Cyanotic patients were less likely to reach an RER of 1.0 compared with noncyanotic ACHD patients (P<0.001), with only 50% of cyanotic patients reaching this value in our study. In healthy subjects, chronic heart failure patients, and acyanotic ACHD patients, RER and peak
O2 were related. However, a gradual decline in correlation coefficients between RER and peak
O2 was found from healthy individuals over heart failure patients to acyanotic ACHD patients (r=0.70 to r=0.50 and r=0.39, respectively; P<0.01 for each). In contrast there was no such correlation in cyanotic ACHD patients (r=0.09, P=0.50). In addition, patients with an RER <1.0 had no significantly different prognosis compared with patients with an RER >1.0 (log-rank P=0.08; indeed, the trend was toward a worse prognosis).
Predictors of Hospitalization or Death
Follow-up data were available for 328 patients. During a median follow-up of 304 days from index cardiopulmonary exercise testing (range, 17 to 580 days), 60 patients (17.9%) were hospitalized for a total of 454 days. The median hospitalization frequency was 1 (range, 1 to 6), with a median hospitalization of 4 days (range, 1 to 54 days). Nine patients (2.7%) died; hospital admission or death occurred in 62 patients (18.5%).
Peak
O2 as a continuous variable significantly predicted the combined end point of hospitalization or death (P=0.02) and death alone (P=0.04). The area under the receiver-operating characteristics curve was 0.75 (95% CI, 0.63 to 0.85) for death alone and 0.68 (95% CI, 0.63 to 0.73) for hospitalization or death. Peak
O2 <15.5 mL · kg1 · min1 (corresponding to the 25th percentile for peak
O2 in our sample) conferred a higher risk of hospitalization or death (hazard ratio, 2.9; 95% CI, 2.2 to 7.4; P<0.0001) and death alone (hazard ratio, 5.6; 95% CI, 1.4 to 31.2; P=0.02) than higher peak
O2 values (Figure 4). Other predictors of hospitalization or death on single-variable analysis were diagnosis, NYHA class, age at surgery, and peak heart rate. Age, gender, body mass index, cyanosis, %FEV1, %FVC, resting heart rate, resting blood pressure, creatinine, sodium, and peak blood pressure were not related to hospitalization or death on single-variable analysis.
|
On multivariable Cox analysis, only peak
O2 (hazard ratio, 0.94 per mL · kg1 · min1; P=0.01) and NYHA class (hazard ratio, 2.15 with each increase in NYHA class; P=0.002) predicted hospitalization or death during follow-up (Table 5). Furthermore, peak
O2 was related to the frequency [exp(ß)=0.91; 95% CI, 0.85 to 0.98; P=0.01] and duration [exp(ß)=0.90; 95% CI, 0.83 to 0.98; P=0.01] of hospitalization adjusted for follow-up time, even after accounting for NYHA class, age, age at surgery, gender, and laboratory parameters.
|
| Discussion |
|---|
|
|
|---|
Exercise Intolerance in Different ACHD Subgroups
Peak
O2 is an established and reliable measure of exercise intolerance that is widely used to assess patients with heart failure.3,4 We found a significantly reduced peak
O2 across the spectrum of ACHD compared with healthy subjects of similar age. This finding is consistent with prior studies that have reported exercise limitation in ACHD patients.510 Our study extends this previous work, showing that the degree of exercise intolerance is related to underlying anatomical features. Patients with simple, noncyanotic lesions with biventricular hearts without pulmonary arterial hypertension had a far better exercise capacity than patients with complex or cyanotic lesions with pulmonary arterial hypertension.
Patients with Eisenmenger physiology and complex anatomies (comprising mainly those with single-ventricle physiology) exhibited a markedly impaired exercise capacity in the present study. Despite being congenitally or surgically "corrected," patients with TGA also had significantly reduced peak
O2 values compared with healthy subjects. Most congenitally corrected TGA patients had associated lesions, potentially explaining their worse peak
O2 values compared with Mustard patients. It should also be emphasized that atrial septal defect closure was performed late in most of the atrial septal defect patients included in our study, who themselves represent the oldest patient subgroup. In contrast, higher peak
O2 values were recorded in patients with a ventricular septal defect who underwent early surgical repair and were significantly younger than atrial septal defect patients.
Exercise Intolerance and NYHA Class
The NYHA classification, originally established for patients with chronic heart failure, is now widely used in congenital heart disease. It represents a simple classification of exercise intolerance based on subjective symptoms. To the best of our knowledge, there are no data assessing the relationship between peak
O2 and functional class in a large cohort of ACHD patients. In our study, NYHA class does stratify patients, distinguishing patients with mild impairment from those with moderate or severe impairment of objective exercise capacity. However, our results also suggest that NYHA class underestimates the true degree of exercise limitation in ACHD patients. Even asymptomatic ACHD patients exhibit markedly impaired peak oxygen consumption, 42% below healthy subjects. It is likely that ACHD patients have made lifelong adaptations to their cardiovascular disease and its slow progression, so they are not aware of the true extent of their exercise intolerance. In our study, ACHD patients had exercise capacities as poor as those of patients with acquired chronic heart failure, even though the latter were much older.
Other Correlates of Exercise Intolerance in ACHD
So far, only limited attempts have been made to assess systematically the impact of different physiological variables on exercise capacity across the spectrum of ACHD. For example, it is unknown to what extent cardiac function correlates with exercise capacity in ACHD. Our results suggest that exercise intolerance in these patients is multifactorial. Numerous variables were associated with peak
O2. Systemic and pulmonary ventricular function determined peak
O2 on single-variable regression. However, after accounting for other variables related to peak
O2, ventricular function had no additional predictive value. In contrast, peak heart rate and pulmonary function were the most powerful predictors of exercise capacity across the spectrum of ACHD even after accounting for NYHA class. Not surprisingly, therefore, factors that impair chronotropic response to exercise such as ß-blockade or abnormal cardiac rhythm were associated with a lower peak
O2. Previous studies have shown that some ACHD patients have impaired pulmonary function15 and depressed peak heart rate.5 The present study extends these findings by demonstrating that both heart rate response and pulmonary function correlate positively with peak
O2 even after accounting for other physiological parameters. In addition, our study demonstrates that pulmonary arterial hypertension and cyanosis are strong correlates of poor exercise capacity and that the combination of both, as in patients with Eisenmenger physiology, severely affects exercise capacity.
Despite including all correlates of peak oxygen consumption in a best model, 46% of the variance in peak
O2 remained unexplained. This finding is consistent with reports from noncongenital heart failure patients.16
Exercise Intolerance Identifies Patients at Risk of Hospitalization or Death
Hospitalization is a major hazard for ACHD patients, associated with substantial costs and an amplified risk of subsequent mortality.17,18 Risk assessment has the potential to assist therapeutic targeting and appropriate resource allocation for ACHD services.
The present study demonstrates that peak
O2 is a predictor of hospitalization or death even after accounting for age, gender, NYHA class, laboratory parameters, and underlying cardiac lesion in contemporary ACHD patients. Patients with a worse exercise capacity were more likely to be admitted to hospital and spent more days hospitalized than patients with higher peak
O2 values. Patients with a peak
O2 <15.5 mL · kg1 · min1 (lowest quartile) demonstrated a 2.9-fold increased risk of hospital admission or death compared with patients with a peak
O2
15.5 mL · kg1 · min1. The results of the present study indicate that in addition to peak
O2, higher NYHA class is associated with an increased risk of hospitalization or death. Although NYHA class is used widely, the underlying criteria are subjective and the reproducibility is low.2 In contrast to NYHA, peak
O2 is a continuous variable that represents a more objective and reproducible method19 for assessing the severity of exercise limitation.20
Peak
O2 predicted all-cause mortality in ACHD patients. However, because of the small number of deaths in our study, multivariable survival analysis was not possible.
Study Limitations
Ventricular function was assessed semiquantitatively at rest with transthoracic echocardiography by a single experienced investigator. Additional imaging with cardiac magnetic resonance and possibly assessment of cardiac function during exercise may show stronger correlations with peak
O2. The population of ACHD patients used in this study reflects the clinical and research workload of a tertiary ACHD center. Hence, we cannot exclude the possibility that the patients in the study could be a biased sample, favoring those with more symptoms and lower perceived functional capacity. Further studies with secondary and community-based ACHD patients with longer follow-up may provide additional insights into the correlates of exercise intolerance and should examine the potential benefits of physical training on exercise capacity, hospitalization, and survival in this patient group. Our study did not specifically address coronary artery disease and its potential contribution to exercise intolerance. However, the population was young (mean age, 33 years), and only 4 patients had a history of coronary disease or coronary intervention. Finally, a larger study may allow sufficient power to identify the prognostic value of peak
O2 within individual anatomic subgroups of ACHD.
Conclusions
Exercise intolerance is prevalent in ACHD, even among asymptomatic patients, and is as severe as it is in patients with noncongenital heart failure. Chronotropic response to exercise, pulmonary arterial hypertension, and impaired pulmonary function are important correlates of exercise intolerance, as is the underlying cardiac anatomy. Impaired exercise capacity is associated with an increased risk of hospitalization or death (independent of symptom status), suggesting that measurement of peak oxygen consumption should be incorporated in the routine, periodic assessment of ACHD patients because it may serve as a useful prognostic tool.
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
2. Rostagno C, Galanti C, Cormeglio M, Boddi V, Olivo G, Gastone Neri Serneri G. Comparison of different methods of functional evaluation in patients with chronic heart failure. Eur J Heart Fail. 2000; 2: 273280.[CrossRef][Medline] [Order article via Infotrieve]
3. Itoh H, Taniguchi K, Koike A, Doi M. Evaluation of severity of heart failure using ventilatory gas analysis. Circulation. 1990; 81 (suppl II): II-31II-37.[Medline] [Order article via Infotrieve]
4. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure: the V-HeFT VA Cooperative Studies Group. Circulation. 1993; 87 (suppl V): V-I5V-16.[Medline] [Order article via Infotrieve]
5. Fredriksen PM, Veldtman G, Hechter S, Therrien J, Chen A, Warsi MA, Freeman M, Liu P, Siu S, Thaulow E, Webb G. Aerobic capacity in adults with various congenital heart diseases. Am J Cardiol. 2001; 87: 310314.[CrossRef][Medline] [Order article via Infotrieve]
6. Fredriksen PM, Therrien J, Veldtman G, Ali Warsi M, Liu P, Thaulow E, Webb G. Aerobic capacity in adults with tetralogy of Fallot. Cardiol Young. 2002; 12: 554559.[CrossRef][Medline] [Order article via Infotrieve]
7. Hechter SJ, Webb G, Fredriksen PM. Benson L, Merchant N, Freeman M, Veldtman G, Warsi MA, Siu S, Liu P. Cardiopulmonary exercise performance in adult survivors of the Mustard procedure. Cardiol Young. 2001; 11: 407414.[CrossRef][Medline] [Order article via Infotrieve]
8. Fredriksen PM, Chen A, Veldtman G, Hechter S, Therrien J, Webb G. Exercise capacity in adult patients with congenitally corrected transposition of the great arteries. Heart. 2001; 85: 191195.
9. Harrison DA, Liu P, Walters JE, Goodman JM, Siu SC, Webb GD, Williams WG, McLaughlin PR. Cardiopulmonary function in adult patients late after Fontan repair. J Am Coll Cardiol. 1995; 26: 10161021.[Abstract]
10. Glaser S, Opitz CF, Bauer U, Wensel R, Ewert R, Lange PE, Kleber FX. Assessment of symptoms and exercise capacity in cyanotic patients with congenital heart disease. Chest. 2004; 125: 368376.[Medline] [Order article via Infotrieve]
11. Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J. 2004; 24: 22432278.
12. Francis DP, Shamim W, Davies LC, Piepoli MF, Ponikowski P, Anker SD, Coats AJ. Cardiopulmonary exercise testing for prognosis in chronic heart failure. Eur Heart J. 2000; 21: 154161.
13. Gatzoulis MA, Clark AL, Cullen S, Claus GH, Redington AN. Right ventricular diastolic function 15 to 35 years after repair of tetralogy of Fallot. Circulation. 1995; 91: 17751781.
14. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, Coats AJ, Anker SD. Gatzoulis MA. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002; 106: 9299.
15. Fredriksen PM, Therrien J, Veldtman G, Warsi MA, Liu P, Siu S, Williams W, Granton J, Webb G. Lung function and aerobic capacity in adult patients following modified Fontan procedure. Heart. 2001; 85: 295299.
16. Gullestad L, Myers J, Edvardsen T, Kjekshus J, Geiran O, Simonsen S. Predictors of exercise capacity and the impact of angiographic coronary artery disease in heart transplant recipients. Am Heart J. 2004; 147: 4954.[CrossRef][Medline] [Order article via Infotrieve]
17. Kaemmerer H, Fratz S, Bauer U, Oechslin E, Brodherr-Heberlein S, Zrenner B, Turina J, Jenni R, Lange PE, Hess J. Emergency hospital admissions and three-year survival of adults with and without cardiovascular surgery for congenital cardiac disease. J Thorac Cardiovasc Surg. 2003; 126: 10481052.
18. Moons P, Siebens K, De Geest S, Abraham I, Budts W, Gewillig M. A pilot study of expenditures on, and utilization of resources in, health care in adults with congenital heart disease. Cardiol Young. 2001; 11: 301313.[CrossRef][Medline] [Order article via Infotrieve]
19. Koike A, Hiroe M, Adachi H, Yajima T, Nogami A, Ito H, Takamoto T, Taniguchi K, Marumo F. Anaerobic metabolism as an indicator of aerobic function during exercise in cardiac patients. J Am Coll Cardiol. 1992; 20: 120126.[Abstract]
20. Lipkin DP. The role of exercise testing in chronic heart failure. Br Heart J. 1987; 58: 559566.
This article has been cited by other articles:
![]() |
G. Smith, J. T. Reyes, J. L. Russell, and T. Humpl Safety of Maximal Cardiopulmonary Exercise Testing in Pediatric Patients With Pulmonary Hypertension Chest, May 1, 2009; 135(5): 1209 - 1214. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Giardini, A. Hager, A. E. Lammers, G. Derrick, J. Muller, G.-P. Diller, K. Dimopoulos, D. Odendaal, G. Gargiulo, F. M. Picchio, et al. Ventilatory efficiency and aerobic capacity predict event-free survival in adults with atrial repair for complete transposition of the great arteries. J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1548 - 1555. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Wald, I. Haber, R. Wald, A. M. Valente, A. J. Powell, and T. Geva Effects of Regional Dysfunction and Late Gadolinium Enhancement on Global Right Ventricular Function and Exercise Capacity in Patients With Repaired Tetralogy of Fallot Circulation, March 17, 2009; 119(10): 1370 - 1377. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gratz, J. Hess, and A. Hager Self-estimated physical functioning poorly predicts actual exercise capacity in adolescents and adults with congenital heart disease Eur. Heart J., February 2, 2009; 30(4): 497 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Senzaki, Y. Iwamoto, H. Ishido, S. Masutani, M. Taketazu, T. Kobayashi, T. Katogi, and S. Kyo Ventricular-Vascular Stiffening in Patients With Repaired Coarctation of Aorta: Integrated Pathophysiology of Hypertension Circulation, September 30, 2008; 118(14_suppl_1): S191 - S198. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Provencher, P. Herve, O. Sitbon, M. Humbert, G. Simonneau, and D. Chemla Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension Eur. Respir. J., August 1, 2008; 32(2): 393 - 398. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Paridon, P. D. Mitchell, S. D. Colan, R. V. Williams, A. Blaufox, J. S. Li, R. Margossian, S. Mital, J. Russell, J. Rhodes, et al. A Cross-Sectional Study of Exercise Performance During the First 2 Decades of Life After the Fontan Operation J. Am. Coll. Cardiol., July 8, 2008; 52(2): 99 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Dimopoulos, G.-P. Diller, E. Koltsida, A. Pijuan-Domenech, S. A. Papadopoulou, S. V. Babu-Narayan, T. V. Salukhe, M. F. Piepoli, P. A. Poole-Wilson, N. Best, et al. Prevalence, Predictors, and Prognostic Value of Renal Dysfunction in Adults With Congenital Heart Disease Circulation, May 6, 2008; 117(18): 2320 - 2328. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Haddad, R. Doyle, D. J. Murphy, and S. A. Hunt Right Ventricular Function in Cardiovascular Disease, Part II: Pathophysiology, Clinical Importance, and Management of Right Ventricular Failure Circulation, April 1, 2008; 117(13): 1717 - 1731. [Full Text] [PDF] |
||||
![]() |
National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF] |
||||
![]() |
National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF] |
||||
![]() |
J.G. Coghlan and J. Davar How should we assess right ventricular function in 2008? Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H22 - H28. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-P. Diller, K. Dimopoulos, H. Kafka, S. Y. Ho, and M. A. Gatzoulis Model of chronic adaptation: right ventricular function in Eisenmenger syndrome Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H54 - H60. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Pinto, B. S. Marino, G. Wernovsky, S. D. de Ferranti, A. Z. Walsh, M. Laronde, K. Hyland, S. O. Dunn Jr, and M. S. Cohen Obesity Is a Common Comorbidity in Children With Congenital and Acquired Heart Disease Pediatrics, November 1, 2007; 120(5): e1157 - e1164. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Dupuis Endothelin: setting the scene in PAH Eur. Respir. Rev., August 1, 2007; 16(102): 3 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Padalino, S. Speggiorin, G. Rizzoli, G. Crupi, V. L. Vida, M. Bernabei, G. Gargiulo, A. Giamberti, F. Santoro, C. Vosa, et al. Midterm results of surgical intervention for congenital heart disease in adults: An Italian multicenter study J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 106 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-P. Diller and M. A. Gatzoulis Pulmonary Vascular Disease in Adults With Congenital Heart Disease Circulation, February 27, 2007; 115(8): 1039 - 1050. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Canter, R. E. Shaddy, D. Bernstein, D. T. Hsu, M. R.K. Chrisant, J. K. Kirklin, K. R. Kanter, R. S.D. Higgins, E. D. Blume, D. N. Rosenthal, et al. Indications for Heart Transplantation in Pediatric Heart Disease: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group Circulation, February 6, 2007; 115(5): 658 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. Milani, C. J. Lavie, M. R. Mehra, and H. O. Ventura Understanding the Basics of Cardiopulmonary Exercise Testing Mayo Clin. Proc., December 1, 2006; 81(12): 1603 - 1611. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Webb and M. A. Gatzoulis Atrial Septal Defects in the Adult: Recent Progress and Overview Circulation, October 10, 2006; 114(15): 1645 - 1653. [Full Text] [PDF] |
||||
![]() |
N. Galie, M. Beghetti, M. A. Gatzoulis, J. Granton, R. M.F. Berger, A. Lauer, E. Chiossi, M. Landzberg, and for the Bosentan Randomized Trial of Endothelin An Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Circulation, July 4, 2006; 114(1): 48 - 54. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Dimopoulos, D. O. Okonko, G.-P. Diller, C. S. Broberg, T. V. Salukhe, S. V. Babu-Narayan, W. Li, A. Uebing, S. Bayne, R. Wensel, et al. Abnormal Ventilatory Response to Exercise in Adults With Congenital Heart Disease Relates to Cyanosis and Predicts Survival Circulation, June 20, 2006; 113(24): 2796 - 2802. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |